COVID-19

CHARLOTTE, N.C. — Withholding immunosuppressive therapy prior to or following COVID-19 vaccination did not impact the rate of breakthrough infection or hospitalizations in patients with inflammatory bowel disease, noted a presenter here.

Rural and American Indian and Alaska Native populations face significant distance barriers to COVID-19 test-to-treat sites, a recent study in JAMA Open Network found.

Novavax’s original COVID-19 vaccine and omicron subvariant vaccine candidate were both successful in a phase 3 trial, according to the company.

Osteopathic manipulation treatment may be an effective treatment option for alleviating post-COVID symptoms, according to a speaker at the American Osteopathic Association’s OMED conference.

Moderna said Monday that data from a phase 2/3 trial showed that its bivalent COVID-19 booster shot triggers a higher antibody response against SARS-CoV-2 omicron subvariants than its original vaccine.

Although clinical and cycle threshold value assessment can distinguish COVID-19 reinfection from detecting virus from a prior infection, it failed to identify 33% of genomically supported reinfections, according to a recent study.

CHICAGO — Routine antithrombotic use on top of usual care did not improve outcomes in high-risk, medically ill outpatients with SARS-CoV-2 infection vs. placebo, a speaker reported.

PHILADELPHIA — Outpatient therapies for COVID-19 are largely being limited by evolving variants’ ability to evade effectiveness, and remaining therapies require careful management, according to a speaker at ACR Convergence 2022.

PHILADELPHIA — The understanding of long COVID, its symptoms and even its definition, continues to rapidly change amid a flood of data, according to Leonard H. Calabrese, DO, and Alfred Kim, MD, PhD, at ACR Convergence 2022.

PHILADELPHIA — Looking not only to history, but also to narratives like novels and movies, can help health care professionals understand and move beyond the COVID-19 pandemic, according to the keynote speaker at ACR Convergence 2022.